top of page

Dr. Rob Holt

C3 IMPACT-MB

Scientific Co-Director, Immunotherapy Program

BC Cancer

Professor of Medical Genetics

University of British Columbia

Professor of Molecular Biology & Biochemistry

Simon Fraser University

Dr. Holt's lab at the BC Genome Science Centre has been engaged in tumor microbiome analysis for 15+ years and he was one of three Scientific Advisors to the NIH funded Human Microbiome Project, initiated in 2008. Currently, Dr. Holt is an investigator on the OPTIMISTICC (Opportunity To Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer) project funded by the Cancer Research UK Grand Challenges program (https://www.optimisticc.org/), that aims to comprehensively map the colorectal cancer microbiome and develop microbiome-targeted therapies for colorectal cancer. He co-leads Work Package 6 of this program with the goal developing vaccines against oncomicrobes linked to colorectal cancer. Dr. Holt's lab initially identified the link between F.nucleatum and colorectal cancer using the same metagenomic approach we will deploy in the C3-IMPACT-MB research project to profile the cholangiocarcinoma microbiome and identify targetable links.

Dr. Rob Holt
bottom of page